Loading clinical trials...
Loading clinical trials...
Pilot Study on Efficacy and Tolerance of Peg-interferon Alpha-2a (Pegasys) Added to Tenofovir DF and Emtricitabine (Truvada) in AGHBe Positive HBV-HIV Co-infected Patients. ANRS HB 01 EMVIPEG.
Conditions
Interventions
TRUVADA (EMTRICITABINE + TENOFOVIR DF)
PEGASYS 180μg (Interféron pégylé alpha -2a)
Locations
2
France
Service des Maladies Infectieuses CHU
Dijon, France
Service d'Hépato-Gastroentérologie Hopital Hôtel-Dieu
Lyon, France
Start Date
January 1, 2007
Primary Completion Date
May 1, 2011
Completion Date
October 1, 2012
Last Updated
January 15, 2015
NCT07024641
NCT06694805
NCT04142047
NCT07428330
NCT07225530
NCT06665646
Lead Sponsor
French National Agency for Research on AIDS and Viral Hepatitis
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions